Schwab Charles Investment Management Inc. cut its position in shares of Cryolife Inc (NYSE:CRY) by 1.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 175,709 shares of the medical equipment provider’s stock after selling 2,909 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Cryolife were worth $3,523,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas purchased a new position in Cryolife during the fourth quarter worth about $197,000. Metropolitan Life Insurance Co. NY purchased a new position in Cryolife in the fourth quarter valued at about $203,000. Victory Capital Management Inc. boosted its stake in Cryolife by 98.4% in the first quarter. Victory Capital Management Inc. now owns 12,594 shares of the medical equipment provider’s stock valued at $253,000 after acquiring an additional 6,246 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in Cryolife in the fourth quarter valued at about $330,000. Finally, Mackenzie Financial Corp boosted its stake in Cryolife by 42.4% in the fourth quarter. Mackenzie Financial Corp now owns 24,489 shares of the medical equipment provider’s stock valued at $469,000 after acquiring an additional 7,297 shares during the last quarter. Institutional investors and hedge funds own 67.56% of the company’s stock.
A number of research analysts have weighed in on CRY shares. ValuEngine cut shares of Cryolife from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Northland Securities reiterated a “buy” rating and issued a $23.50 target price on shares of Cryolife in a research note on Thursday, March 8th. Canaccord Genuity reiterated a “buy” rating and issued a $28.00 target price (up from $25.00) on shares of Cryolife in a research note on Friday, March 9th. Finally, Zacks Investment Research cut shares of Cryolife from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $26.88.
Cryolife opened at $27.60 on Friday, according to MarketBeat.com. The company has a debt-to-equity ratio of 0.77, a quick ratio of 3.72 and a current ratio of 5.07. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 84.39 and a beta of 0.78. Cryolife Inc has a twelve month low of $16.80 and a twelve month high of $29.55.
Cryolife (NYSE:CRY) last released its earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.02 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.02. The firm had revenue of $61.95 million for the quarter, compared to analysts’ expectations of $60.30 million. Cryolife had a negative net margin of 1.15% and a positive return on equity of 4.55%. The company’s quarterly revenue was up 37.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.09 earnings per share. research analysts anticipate that Cryolife Inc will post 0.29 earnings per share for the current fiscal year.
In related news, CAO Amy Horton sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $25.94, for a total transaction of $103,760.00. Following the sale, the chief accounting officer now directly owns 98,959 shares in the company, valued at approximately $2,566,996.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director C Elkins Ronald sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 14th. The shares were sold at an average price of $28.89, for a total transaction of $144,450.00. Following the sale, the director now owns 70,997 shares in the company, valued at $2,051,103.33. The disclosure for this sale can be found here. Insiders have sold a total of 51,191 shares of company stock worth $1,332,075 over the last 90 days. 3.97% of the stock is currently owned by corporate insiders.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryolife Inc (NYSE:CRY).
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.